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Background: Different flavonoids are known to interfere with influenza A virus replication. Recently, we showed
that the structurally similar flavonoids baicalein and biochanin A inhibit highly pathogenic avian H5N1 influenza A
virus replication by different mechanisms in A549 lung cells. Here, we investigated the effects of both compounds
on H5N1-induced reactive oxygen species (ROS) formation and the role of ROS formation during H5N1 replication.
Findings: Baicalein and biochanin A enhanced H5N1-induced ROS formation in A549 cells and primary human
monocyte-derived macrophages. Suppression of ROS formation induced by baicalein and biochanin A using the
antioxidant N-acetyl-L-cysteine strongly increased the anti-H5N1 activity of both compounds in A549 cells but not
in macrophages.
Conclusions: These findings emphasise that flavonoids induce complex pharmacological actions some of which
may interfere with H5N1 replication while others may support H5N1 replication. A more detailed understanding
of these actions and the underlying structure-activity relationships is needed to design agents with optimised
anti-H5N1 activity.
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Highly pathogenic influenza A viruses including H5N1 vi-
ruses represent a major pandemic threat. Complication
rates are much higher in H5N1 patients than in seasonal
influenza or pandemic H1N1/09 patients [1-4]. As of 24th
January 2014, 650 confirmed human H5N1 cases had
resulted in 386 deaths (www.who.int).
During an initial pandemic phase, matched vaccines will
be restricted and antiviral drugs will be critical. The efficacy
of the approved anti-influenza drugs (adamantanes, neur-
aminidase inhibitors) is limited, resistant strains emerge, and
H5N1 strains appear to be less sensitive to the established
anti-influenza drugs than seasonal influenza strains [1,4-13].
Hence, additional anti-influenza therapies are needed.
In 2009, the “WHO public health research agenda for
Influenza” expressed a need for additional drugs including* Correspondence: cinatl@em.uni-frankfurt.de
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mended to investigate natural products for anti-influenza
activity (www.who.int). Flavonoids are known to exert
multiple pharmacological effects including anti-inflamma-
tory and anti-viral activities including inhibition of seasonal
influenza A (H1N1) viruses [14-19]. They may interfere
with the influenza virus neuraminidase [19-21], the virus
host cell uptake [20,22], or cellular signalling events like
the activation of nuclear factor kB (NFkB), AKT, ERK 1/2,
p38, and/or JNK [23-27]. We showed recently that the fla-
vonoids biochanin A and baicalein interfere with H5N1
replication in lung epithelial cells but that only baicalein
inhibited H5N1 replication in primary human monocyte-
derived macrophages [28]. Although biochanin A and
baicalein are closely related structures (Figure 1A), they
differed in their antiviral mechanisms. Inhibition of the
H5N1 neuraminidase appeared to substantially contribute
to the anti-H5N1 effects exerted by baicalein but not
by biochanin A. Biochanin A interfered in contrast to
baicalein with H5N1-induced activation of constituents of
cellular signalling pathways [28] that are known to beal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Effects of baicalein and biochanin on reactive oxygen species (ROS) formation in A549 cells infected with H5N1 strain
A/Thailand/1(Kan-1)/04. A549 cells were treated continuously with the investigated flavonoids and/ or N-acetyl-L-cysteine (NAC) starting with a
1 h pre-incubation period prior to infection with H5N1 strain A/Thailand/1(Kan-1)/04 (MOI 0.01). ROS formation was detected at 24 h post
infection. A) Chemical structures of biochanin A and baicalein; B) Effects of different baicalein or biochanin A concentrations on H5N1-induced
ROS formation. *P < 0.05 relative to virus control; C) Effects of N-acetyl-L-cysteine (NAC) 5 mM on baicalein 40 μM- or biochanin A 40 μM-induced
ROS formation in H5N1-infected A549 cells. ‘-’ indicates absence of virus or respective compound, ‘+’ indicates presence of virus or respective
compound. *P < 0.05 relative to virus control, #P < 0.05 relative to respective flavonoid alone. Values are presented as mean ± S.D. from three
different independent experiments.
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1/2, and NFκB [10,29-32]. Notably, the effects of baicalein
and biochanin A on H5N1 replication are complex and
additional antiviral mechanisms are likely to contribute to
their anti-H5N1 activities.
Flavonoids are known to differ in their effects on the
formation of reactive oxygen species (ROS). They may
display anti- or pro-oxidative effects [33]. Influenza virus
replication is influenced by the cellular redox status [34].
The inhibition of virus-induced ROS formation by differentstrategies including the use of the antioxidant N-acetyl-L-
cysteine (NAC) was shown to inhibit influenza A
virus replication including H5N1 strains [34-36]. Here, we
investigated the effects of baicalein and biochanin A on
H5N1-induced ROS formation and the combined effects
of baicalein and biochanin A in combination with the
antioxidant NAC on H5N1 replication.
A549 cells (human lung carcinoma; ATCC, Manassass,
VA, USA: CCL-185) and Vero cells (African green monkey
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Figure 2 Effects of baicalein and biochanin A on H5N1 titres in
combination with N-acetyl-L-cysteine (NAC). A549 cells were
infected with H5N1 strain A/Thailand/1(Kan-1)/04 (MOI 0.01). Drugs
were continuously present starting with a 1 h pre-incubation period.
Virus titres were determined 48 h post infection. A) Effects of NAC
on H5N1 replication, *P < 0.05 relative to virus control; B) Effects of
NAC on H5N1 titres in the presence of the flavonoids baicalein
40 μM or biochanin A 40 μM, *P < 0.05 relative to flavonoid alone.
Values are presented as mean ± S.D. from three different independent
experiments.
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buffy coats of healthy donors (Institute of Transfusion
Medicine and Immune Haematology, German Red Cross
Blood Donor Centre, Goethe-University, Frankfurt/Main,
Germany) and CD14+ monocytes were differentiated into
MDMs as described previously [28]. Cells were infected
with H5N1 strain A/Thailand/1(Kan-1)/04 (obtained from
Dr. Puthavathana, Mahidol University, Bangkok, Thailand)
and virus titres were determined as 50% tissue culture
infectious dose (TCID50/mL) as described previously [28].
Flavonoids, NAC, or their combinations were present
starting from a 1 h pre-incubation period prior to infec-
tion. For the identification of statistically significant differ-
ences (P < 0.05), two groups were compared by Student’s
t-test, more groups by ANOVA followed by subsequent
stepwise multiple comparison procedure using the Student-
Newman-Keuls method.
H5N1 infection of A549 cells at a multiplicity of infec-
tion (MOI) 0.01 resulted in enhanced ROS formation
compared to control 24 h after infection (Figure 1B) as
indicated by the use of the Image-iT LIVE Green Reactive
Oxygen Species Kit (Molecular Probes, distributed by
Invitrogen, Karlsruhe, Germany). Baicalein and biochanin
A (both obtained from Indofine Chemical Company,
Hillsborough, NJ, USA) did not influence ROS levels in
non-infected or H5N1-infected cells in concentrations up
to 20 μM. However, at a concentration of 40 μM both
compounds increased the ROS levels in non-infected as
well as H5N1-infected cells (Figure 1B) despite the differ-
ences in their modes of anti-H5N1 action [28]. An NAC
(obtained from Alexis, distributed by Axxora, Germany,
dissolved in unsupplemented MEM and adjusted to
pH 7.4 with NaOH) concentration of 5 mM was sufficient
to reduce the ROS levels below the levels observed in
non-treated H5N1-infected A549 cells (Figure 1C).
Next, we investigated whether the reduction of baica-
lein- or biochanin A-induced enhanced ROS levels in
H5N1-infected A549 cells by NAC influences the antiviral
effects of these flavonoids. H5N1 (MOI 0.01)-infected
A549 cells were treated with baicalein 40 μM or biochanin
A 40 μM in combination with NAC in concentrations
ranging from 1.25 to 5 mM. NAC did not affect cell viabil-
ity alone or in combination with baicalein or biochanin A
in the investigated concentrations as indicated by the
CellTiter-Glo® Luminescent Cell Viability Assay (Promega
GmbH, Mannheim, Germany) (data not shown). While
NAC 5 mM alone moderately reduced H5N1 titres (2.2-
fold reduction), NAC 2.5 mM or 1.25 mM did not sig-
nificantly affect virus titres (Figure 2A). However, NAC
reduced H5N1 titres in combination with baicalein or
biochanin A in a dose-dependent manner in this con-
centration range in A549 cells (Figure 2B). Notably,
NAC also inhibited baicalein- and biochanin A-induced oxi-
dative stress in H5N1-infected primary human monocyte-
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in this cell type (Figure 3). Human monocytes had been
isolated from buffy coats of healthy donors, obtained
from the Institute of Transfusion Medicine and Immune
Haematology, German Red Cross Blood Donor Center,
Johann Wolfgang Goethe-University, Frankfurt am Main.
In conclusion, we show that two flavonoids that interfere
with H5N1 replication by different mechanisms of action
exert similar effects at the level of ROS induction. Baicalein
interferes with the H5N1 neuraminidase activity but bio-
chanin does not. Biochanin A (but not baicalein) inhibits
the activation of signalling molecules involved in H5N1-
induced signalling including AKT, ERK 1/2, and NFκB [28].
Despite these differences in their anti-H5N1 mechanisms,
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Figure 3 Effects of baicalein and biochanin A on reactive oxygen spe
monocyte-derived macrophages in combination with N-acetyl-L-cyste
(Kan-1)/04 (MOI 1). Drugs were continuously present starting with a 1 h pre
A) Effects of flavonoids 40 μM and/or NAC 5 mM on H5N1-induced ROS form
presence of virus or respective compound. *P < 0.05 relative to flavonoids alo
absence of NAC 5 mM on H5N1 titres. ‘-’ indicates absence of virus or resp
compound. Values are presented as mean ± S.D. from three different indein A549 cells, and the efficacy of both compounds was en-
hanced by the antioxidant NAC. In contrast, inhibition of
flavonoid-induced ROS formation by NAC did not affect
virus replication in H5N1-infected macrophages. These
findings emphasise that flavonoids, a class of natural com-
pounds known to exert anti-influenza effects [16-19,28], in-
duce a complex range of pharmacological actions by which
they modify influenza A virus replication including highly
pathogenic avian H5N1 strains. These actions may be cell
type-specific and include pro- and antiviral effects. The
overall activity may be the result of the totality of effects
exerted by a certain flavonoid in a certain cell type. A more
detailed understanding of these actions and the underlying
structure-activity relationships is needed in order to design
structures with optimised anti-influenza activity.+ + + +
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